An Integrated Bioinformatic Investigation of Kallikrein Gene Family Members in Kidney Renel Cell Carcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Aug 8

PMID 39116105

Authors

Baoquan Wang

Lun Yang

Haiyun Qin

Fengzhen Li

Peitong Zhang

Affiliations

Soon will be listed here.

Abstract

Backgrounds: KLKs have been proved to be key regulators of the tumor microenvironment. In this study, we explored the potential of Kallikrein-related peptidases (KLKs) as clinical diagnostic and prognostic markers in patients with kidney renal clear cell carcinoma (KIRC) as well as their relationship with common immuno-inhibitor and immune cell infiltration in the tumor microenvironment to provide new targets and novel ideas for KIRC therapy.

Methods: Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), UCSC Xena, Genotype-Tissue Expression (GTEx), Kaplan-Meier plotter, cBioPortal, STRING, GeneMANIA, and TISIDB were used to analyze the differential expression, prognostic value, gene changes, molecular interaction, and immune infiltration of KLKs in patients with KIRC.

Results: From the gene expression level, it can be determined that KLK1, KLK6, and KLK7 are differentially expressed in KIRC and normal tissues. From the perspective of clinical prognosis, KLK1, KLK13, and KLK14 are highly correlated with the clinical prognosis of KIRC. The expression of KLKs is regulated by various immunosuppressive agents, with KDR, PVRL2, and VTCN1 being the most significant. The expression of KLKs is significantly correlated with the infiltration of various immune cells, of which Eosinophils and Neutrophils are the most significant.

Conclusions: KLK1, KLK6, KLK7, KLK13, and KLK14 have potential as diagnostic and prognostic biomarkers, among which KLK1 is the most significant. This study may provide detailed immune information and promising targets for KIRC immunotherapy to assist in designing new immunotherapies.

References

Mohammad Rezaei F, Hashemzadeh S, Ravanbakhsh Gavgani R, Hosseinpour Feizi M, Pouladi N, Kafil H . Dysregulated and Gene Expression in Colorectal Cancer Patients. Rep Biochem Mol Biol. 2020; 8(3):244-252. PMC: 7103086. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Shah S, Brock E, Ji K, Mattingly R . Ras and Rap1: A tale of two GTPases. Semin Cancer Biol. 2018; 54:29-39. PMC: 6170734. DOI: 10.1016/j.semcancer.2018.03.005. View

Mayor N, Sathianathen N, Buteau J, Koschel S, Anton Juanilla M, Kapoor J . Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020; 126(5):525-535. DOI: 10.1111/bju.15143. View

Gumz M, Zou H, Kreinest P, Childs A, Belmonte L, LeGrand S . Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007; 13(16):4740-9. DOI: 10.1158/1078-0432.CCR-07-0143. View

Filippou P, Karagiannis G, Musrap N, Diamandis E . Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. Crit Rev Clin Lab Sci. 2016; 53(4):277-91. DOI: 10.3109/10408363.2016.1154643. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

Beroukhim R, Brunet J, Di Napoli A, Mertz K, Seeley A, Pires M . Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69(11):4674-81. PMC: 2745239. DOI: 10.1158/0008-5472.CAN-09-0146. View

10.

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

11.

Cutcliffe C, Kersey D, Huang C, Zeng Y, Walterhouse D, Perlman E . Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res. 2005; 11(22):7986-94. DOI: 10.1158/1078-0432.CCR-05-1354. View

12.

Kishibe M . Physiological and pathological roles of kallikrein-related peptidases in the epidermis. J Dermatol Sci. 2019; 95(2):50-55. DOI: 10.1016/j.jdermsci.2019.06.007. View

13.

Song M . Recent developments in small molecule therapies for renal cell carcinoma. Eur J Med Chem. 2017; 142:383-392. DOI: 10.1016/j.ejmech.2017.08.007. View

14.

Devetzi M, Goulielmaki M, Khoury N, Spandidos D, Sotiropoulou G, Christodoulou I . Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review). Int J Mol Med. 2018; 41(3):1177-1186. PMC: 5819898. DOI: 10.3892/ijmm.2018.3361. View

15.

Kuusk T, Grivas N, de Bruijn R, Bex A . The current management of renal cell carcinoma. Minerva Med. 2017; 108(4):357-369. DOI: 10.23736/S0026-4806.17.05058-3. View

16.

Tailor P, Kodeboyina S, Bai S, Patel N, Sharma S, Ratnani A . Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. Oncotarget. 2018; 9(25):17876-17888. PMC: 5915161. DOI: 10.18632/oncotarget.24947. View

17.

Srinivasan S, Kryza T, Batra J, Clements J . Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nat Rev Cancer. 2022; 22(4):223-238. DOI: 10.1038/s41568-021-00436-z. View

18.

Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken W . Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005; 11(16):5730-9. DOI: 10.1158/1078-0432.CCR-04-2225. View

19.

Dorn J, Bayani J, Yousef G, Yang F, Magdolen V, Kiechle M . Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thromb Haemost. 2013; 110(3):408-22. DOI: 10.1160/TH13-03-0206. View

20.

Vivian J, Rao A, Nothaft F, Ketchum C, Armstrong J, Novak A . Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017; 35(4):314-316. PMC: 5546205. DOI: 10.1038/nbt.3772. View